AstraZeneca PLCAZN:LSE

4,167
23.00 / 0.55 %
1.93m
5.79 %
0.5452
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 03 2015 16:53 BST.

Directors & officers

 NameTitleCompensationAgeOfficer
since
 
LeifJohansson
Non-Executive Independent Chairman of the Board
540.00k GBP
66
2012
Mr. Leif Johansson has been appointed as Non-Executive Independent Chairman of the Board of AstraZeneca Plc. Elected as a Director in April 26, 2012 and became Non-Executive Chairman of the Board on June 1, 2012. Leif Johansson is also the Chairman of global telecommunications company, LM Ericsson, a position he has held since April 2011. From 1997 until 2011, he was Chief Executive of AB Volvo, one of the world’s manufacturers of trucks, buses, construction equipment, drive systems and aerospace components. He spent a part of his early career at AB Electrolux, latterly as Chief Executive from 1994 to 1997. He was a Non-Executive Director of BMS from 1998 to September 2011, serving on the board’s audit committee and compensation and management development committee. He is Chairman of the European Round Table of Industrialists and the International Advisory Board of the Nobel Foundation. He holds board positions at Svenska Cellulosa Aktiebolaget SCA and Ecolean AB. He holds an MSc in engineering from Chalmers University of Technology, Gothenburg, and has been a member of the Royal Swedish Academy of Engineering Sciences since 1994. He became Chairman of the Academy in 2012.
 
PascalSoriot
Chief Executive Officer, Executive Director
2.97m GBP
55
2012
 
MarcDunoyer
Chief Financial Officer, Executive Director
259.00k GBP
61
2013
 
RuudDobber
Executive Vice President, Europe
--
--
2013
 
CarolineHempstead
Interim Executive Vice-President, Human Resources & Corporate Affairs
--
--
2013
 
PaulHudson
Executive Vice President, North America
--
--
2013
 
BahijaJallal
Executive Vice President, MedImmune
--
--
2013
 
MarkMallon
Executive Vice President, International
--
--
2013
 
BriggsMorrison
Executive Vice President - Global Medicines Development
--
--
2013
 
MenelasPangalos
Executive Vice President - Innovative Medicines
--
--
2013
 
DavidSmith
Executive Vice President - Operations and Information Services
--
--
2006
 
KatarinaAgeborg
Chief Compliance Officer
--
--
2011
 
JeffreyPott
General Counsel
--
--
2009
 
AdrianKemp
Company Secretary
--
--
2009
 
CorneliaBargmann
Non-Executive Director
--
--
2015
 
GenevieveBerger
Non-Executive Director
--
60
2012
 
AnnCairns
Non-Executive Director
--
57
2014
 
MarcusWallenberg
Non-Executive Director
--
59
1999
 
BruceBurlington
Non-Executive Independent Director
--
65
2010
 
GrahamChipchase
Non-Executive Independent Director
--
52
2012
 
Jean-PhilippeCourtois
Non-Executive Independent Director
--
53
2008
 
RudolphMarkham
Senior Non-Executive Independent Director
--
69
2008
 
ShritiVadera
Non-Executive Independent Director
--
52
2011
 
KarlHard
IR Contact Officer
--
--
2013
 
ColleenProctor
IR Contact Officer
--
--
2013
View all 25 directors & officersOfficers and Directors data as of Jun 27 2015

Director dealings

Directors have sold an average of -4.99k shares during each of the last thirty-six months. Director sales are not usually meaningful unless they are significantly larger than normal.

As of 01 Jul 2015
Mouseover chart for details.
Dealing dateName & titleSharesPer share (GBX)Deal size (GBP)
Purchase
07 May 2015
Mr. M Dunoyer
Chief Financial Officer
10,0004,397439.70k
Purchase
30 Apr 2015
Ms. Ann Cairns
1,1004,45549.01k
Purchase
29 Apr 2015
Baroness Vadera
3,5004,563159.71k
Purchase
29 Apr 2015
Dr. C Cori Bargmann
7004,51431.60k
Purchase
28 Apr 2015
J Courtois
2,5004,536113.40k
1-5 of 7 results
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.